Advertisement

Historical Perspective of Raynaud’s Phenomenon

Chapter
  • 1.4k Downloads

Abstract

Cold-induced vasospastic attacks of the fingers have been described since the eighteenth century. In 1862, Maurice Raynaud reported in his medical school graduation thesis a group of patients with spontaneous gangrene of the extremities and a history of vasospastic attacks. In such patients, fingers or toes turned white upon cold exposure or emotional stress, then cyanotic, and finally hyperemic and red when circulation was restored. Raynaud’s work was translated into English in 1888 and Raynaud’s phenomenon progressively became a worldwide used term to describe vasospastic attacks. In 1932, Allen and Brown defined the first set of classification criteria to differentiate primary Raynaud’s disease from secondary Raynaud’s phenomenon.

The mechanism of Raynaud’s phenomenon has been a 150-year-long enigma. Raynaud proposed that the vasospasm was caused by an overreactivity of the sympathetic nervous system. In 1929, Sir Thomas Lewis challenged such hypothesis showing that a “local fault” of the digital artery was actually responsible. Evidence supporting Raynaud’s or Lewis’ hypotheses alternated during the twentieth century, until the discovery of the molecular basis of cold-induced cutaneous arterial vasoconstriction led over the past decade to a unifying pathogenetic vision reconciling the two theories. Importantly, the deeper understanding of the mechanisms of Raynaud’s phenomenon has allowed the introduction of more effective targeted pharmacological therapies that have profoundly changed the current management of this disease.

Keywords

Local Fault Digital Artery Nailfold Capillaroscopy Thromboangiitis Obliterans Cervical Sympathetic Trunk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

RP

Raynaud’s phenomenon

αAR

Alpha-adrenoreceptor

References

  1. 1.
    Raynaud M. De l’asphyxie locale et de la gangrène symétrique dés extrémites. Paris: L. Leclerc; 1862.Google Scholar
  2. 2.
    Osler W. The principles and practice of medicine. 1st ed. New York: D. Appleton and Co.; 1892.Google Scholar
  3. 3.
    Hutchinson J. Raynaud’s phenomenon. Med Press Circ. 1901;72:403–5.Google Scholar
  4. 4.
    Lewis T. Observations upon the reaction of the vessels of the human skin to cold. Heart. 1929;15:177–208.Google Scholar
  5. 5.
    Lewis T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation of the fingers. A variety of Raynaud’s disease. Heart. 1929;15:7–101.Google Scholar
  6. 6.
    Allen E, Brown G. Raynaud’s disease: a critical review of the minimum requisites for diagnosis. Am J Med Sci. 1932;183:187–200.CrossRefGoogle Scholar
  7. 7.
    Allen E, Brown G. Raynaud’s disease affecting men. Ann Intern Med. 1932;5(11):1384–6.CrossRefGoogle Scholar
  8. 8.
    LeRoy EC, Medsger Jr TA. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10(5):485–8.PubMedGoogle Scholar
  9. 9.
    Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M. Nifedipine and Raynaud’s phenomenon. Ann Intern Med. 1981;94(4 pt 1):546.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith CD, McKendry RJ. Controlled trial of nifedipine in the treatment of Raynaud’s phenomenon. Lancet. 1982;2(8311):1299–301.PubMedCrossRefGoogle Scholar
  11. 11.
    Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon. N Engl J Med. 1983;308(15):880–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Belch JJ, Newman P, Drury JK, Capell H, Leiberman P, James WB, et al. Successful treatment of Raynaud’s Syndrome with prostacyclin. Thromb Haemost. 1981;45(3):255–6.PubMedGoogle Scholar
  13. 13.
    Belch JJ, Newman P, Drury JK, McKenzie F, Capell H, Leiberman P, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud’s syndrome. A double-blind controlled trial. Lancet. 1983;1(8320):313–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Lichtenstein JR. Use of sildenafil citrate in Raynaud’s phenomenon: comment on the article by Thompson et al. Arthritis Rheum. 2003;48(1):282–3. author reply 283.PubMedCrossRefGoogle Scholar
  15. 15.
    Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol. 2000;278(4):H1075–83.PubMedGoogle Scholar
  16. 16.
    Coffman JD. The enigma of primary Raynaud’s disease. Circulation. 1989;80(4):1089–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Olmsted J, Olmsted E. Claude Bernard and the experimental method in medicine. New York: Henry Schuman, Inc.; 1952.Google Scholar
  18. 18.
    Peacock JH. Vasodilatation in the human hand; observations on primary Raynaud’s disease and acrocyanosis of the upper extremities. Clin Sci (Lond). 1958;17(4):575–86.Google Scholar
  19. 19.
    Peacock JH. Peripheral venous blood concentrations of epinephrine and norepinephrine in primary Raynaud’s disease. Circ Res. 1959;7:821–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Kontos HA, Wasserman AJ. Effect of reserpine in Raynaud’s phenomenon. Circulation. 1969;39(2):259–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Romeo SG, Whalen RE, Tindall JP. Intra-arterial administration of reserpine. Its use in patients with Raynaud’s disease or Raynaud’s phenomenon. Arch Intern Med. 1970;125(5):825–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Willerson JT, Thompson RH, Hookman P, Herdt J, Decker JL. Reserpine in Raynaud’s disease and phenomenon. Short-term response to intra-arterial injection. Ann Intern Med. 1970;72(1):17–27.PubMedCrossRefGoogle Scholar
  23. 23.
    Halpern A, Kuhn PH, Shaftel H, Samuels SS, Shaftel N, Selman D, et al. Raynaud’s disease, Raynaud’s phenomenon, and serotonin. Angiology. 1960;11:151–67.PubMedCrossRefGoogle Scholar
  24. 24.
    Freedman RR, Mayes MD, Sabharwal SC. Induction of vasospastic attacks despite digital nerve block in Raynaud’s disease and phenomenon. Circulation. 1989;80(4):859–62.PubMedCrossRefGoogle Scholar
  25. 25.
    Jamieson GG, Ludbrook J, Wilson A. Cold hypersensitivity in Raynaud’s phenomenon. Circulation. 1971;44(2):254–64.PubMedCrossRefGoogle Scholar
  26. 26.
    Olsen N, Petring OU, Rossing N. Exaggerated postural vasoconstrictor reflex in Raynaud’s phenomenon. Br Med J (Clin Res Ed). 1987;294(6581):1186–8.CrossRefGoogle Scholar
  27. 27.
    Freedman RR, Baer RP, Mayes MD. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud’s disease. Circulation. 1995;92(6):1448–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Coffman J, Cohen R. Alpha-2-adrenergic and 5-HT2 receptor hypersensitivity in Raynaud’s disease. J Vasc Med Biol. 1990;2:100.Google Scholar
  29. 29.
    Freedman RR, Sabharal SC, Desai N, Wenig P, Mayes M. Increased alpha-adrenergic responsiveness in idiopathic Raynaud’s disease. Arthritis Rheum. 1989;32(1):61–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Freedman RR, Moten M, Migaly P, Mayes M. Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud’s disease. Arthritis Rheum. 1993;36(5):685–90.PubMedCrossRefGoogle Scholar
  31. 31.
    Lindblad LE, Ekenvall L, Etzell BM, Bevegard S. Adrenoceptors in Raynaud’s disease. J Cardiovasc Pharmacol. 1989;14(6):881–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Osler W, McCrae T. Raynaud’s disease. In: Osler W, McCrae T, editors. Modern medicine: its theory and practice, in original contributions by American and foreign authors, vol. 6. Lea Brothers & Co: Glasgow; 1899. p. 627.Google Scholar
  33. 33.
    Monro T. Raynaud’s disease. James Maclehose & Sons: Glasgow; 1899.Google Scholar
  34. 34.
    Gifford Jr RW, Hines Jr EA. Raynaud’s disease among women and girls. Circulation. 1957;16(6):1012–21.PubMedCrossRefGoogle Scholar
  35. 35.
    Lewis T, Pickering G. Observations upon maladies in which the blood supply to digits ceases intermittently or permanently, and upon bilateral gangrene of digits; observations relevant to so-called “Raynaud’s disease”. Clin Sci. 1933;1:327–66.Google Scholar
  36. 36.
    Cakir N, Pamuk ON, Donmez S, Barutcu A, Diril H, Odabas E, et al. Prevalence of Raynaud’s phenomenon in healthy Turkish medical students and hospital personnel. Rheumatol Int. 2008;29(2):185–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Czirjak L, Kiss CG, Lovei C, Suto G, Varju C, Fuzesi Z, et al. Survey of Raynaud’s phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol. 2005;23(6):801–8.PubMedGoogle Scholar
  38. 38.
    Freedman RR, Mayes MD. Familial aggregation of primary Raynaud’s disease. Arthritis Rheum. 1996;39(7):1189–91.PubMedCrossRefGoogle Scholar
  39. 39.
    Gelber AC, Wigley FM, Stallings RY, Bone LR, Barker AV, Baylor I, et al. Symptoms of Raynaud’s phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidity. J Clin Epidemiol. 1999;52(5):441–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Harada N, Ueda A, Takegata S. Prevalence of Raynaud’s phenomenon in Japanese males and females. J Clin Epidemiol. 1991;44(7):649–55.PubMedCrossRefGoogle Scholar
  41. 41.
    Jones GT, Herrick AL, Woodham SE, Baildam EM, Macfarlane GJ, Silman AJ. Occurrence of Raynaud’s phenomenon in children ages 12-15 years: prevalence and association with other common symptoms. Arthritis Rheum. 2003;48(12):3518–21.PubMedCrossRefGoogle Scholar
  42. 42.
    Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Franco A, Drouet P, et al. Geographic variation in the prevalence of Raynaud’s phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie. France J Rheumatol. 1993;20(1):70–6.Google Scholar
  43. 43.
    Nigrovic PA, Fuhlbrigge RC, Sundel RP. Raynaud’s phenomenon in children: a retrospective review of 123 patients. Pediatrics. 2003;111(4 Pt 1):715–21.PubMedCrossRefGoogle Scholar
  44. 44.
    Purdie G, Harrison A, Purdie D. Prevalence of Raynaud’s phenomenon in the adult New Zealand population. N Z Med J. 2009;122(1306):55–62.PubMedGoogle Scholar
  45. 45.
    Voulgari PV, Alamanos Y, Papazisi D, Christou K, Papanikolaou C, Drosos AA. Prevalence of Raynaud’s phenomenon in a healthy Greek population. Ann Rheum Dis. 2000;59(3):206–10.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Brown G, O’Leary P. Skin capillaries in scleroderma. Arch Intern Med. 1925;36:73–88.CrossRefGoogle Scholar
  47. 47.
    Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum. 1973;16(5):619–28.PubMedCrossRefGoogle Scholar
  48. 48.
    Maricq HR, Downey JA, LeRoy EC. Standstill of nailfold capillary blood flow during cooling in scleroderma and Raynaud’s syndrome. Blood Vessels. 1976;13(6):338–49.PubMedGoogle Scholar
  49. 49.
    Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol. 2000;27(1):155–60.PubMedGoogle Scholar
  50. 50.
    Murray AK, Moore TL, Manning JB, Taylor C, Griffiths CE, Herrick AL. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum. 2009;61(8):1103–11.PubMedCrossRefGoogle Scholar
  51. 51.
    Maricq HR, Jennings JR, Valter I, Frederick M, Thompson B, Smith EA, et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud’s Treatment Study Investigators. Vasc Med. 2000;5(3):135–40.PubMedCrossRefGoogle Scholar
  52. 52.
    White W, Jelliffe S. Angioneuroses and trophoneuroses. In: White W, Jelliffe S, editors. The modern treatment of nervous and mental diseases. 1st ed. USA.: Lea & Febiger; 1913. p. 511–15.Google Scholar
  53. 53.
    Lipkin M, McDevitt E, Schwartz M, Duryee A. On the effects of suggestion in the treatment of vasospastic disorders of the extremities. Psychosom Med. 1945;7:152–9.CrossRefGoogle Scholar
  54. 54.
    Surwit RS. Biofeedback: a possible treatment for Raynaud’s disease. Semin Psychiatry. 1973;5(4):483–90.PubMedGoogle Scholar
  55. 55.
    Surwit RS, Pilon RN, Fenton CH. Behavioral treatment of Raynaud’s disease. J Behav Med. 1978;1(3):323–35.PubMedCrossRefGoogle Scholar
  56. 56.
    McIntyre DR. A maneuver to reverse Raynaud’s phenomenon of the fingers. JAMA. 1978;240(25):2760.PubMedCrossRefGoogle Scholar
  57. 57.
    Kempson GE, Coggon D, Acheson ED. Electrically heated gloves for intermittent digital ischaemia. Br Med J (Clin Res Ed). 1983;286(6361):268.CrossRefGoogle Scholar
  58. 58.
    Peterson LL, Vorhies C. Raynaud’s syndrome. Treatment with sublingual administration of nitroglycerin, swinging arm maneuver, and biofeedback training. Arch Dermatol. 1983;119(5):396–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Turnipseed W, Vasko JS, Evans WE. Hemodynamic effects of intravenous alcohol on patients with ischemic limb disease. J Surg Res. 1976;20(5):477–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Cushing H. Treatment by the tourniquet to counteract the vasomotor spasm of Raynaud’s disease. J Nerv Mental Dis. 1902;29:657.CrossRefGoogle Scholar
  61. 61.
    Adson A, Brown G. Treatment of Raynaud’s disease. JAMA. 1925;84(25):1908.CrossRefGoogle Scholar
  62. 62.
    Royle JP. A history of sympathectomy. Aust N Z J Surg. 1999;69(4):302–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Cerfolio RJ, De Campos JR, Bryant AS, Connery CP, Miller DL, DeCamp MM, et al. The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis. Ann Thorac Surg. 2011;91(5):1642–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Flatt AE. Digital artery sympathectomy. J Hand Surg Am. 1980;5(6):550–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Engelhart M. The effect of sympathetic blockade and cooling in Raynaud’s phenomenon. Clin Physiol. 1990;10(2):131–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Wigley FM. Clinical practice. Raynaud’s phenomenon. N Engl J Med. 2002;347(13):1001–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Neumeister MW. Botulinum toxin type A in the treatment of Raynaud’s phenomenon. J Hand Surg Am. 2010;35(12):2085–92.PubMedCrossRefGoogle Scholar
  68. 68.
    Neumeister MW, Chambers CB, Herron MS, Webb K, Wietfeldt J, Gillespie JN, et al. Botox therapy for ischemic digits. Plast Reconstr Surg. 2009;124(1):191–201.PubMedCrossRefGoogle Scholar
  69. 69.
    Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007;119(1):217–26.PubMedCrossRefGoogle Scholar
  70. 70.
    Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study. Eur J Clin Invest. 2004;34(4):312–3.PubMedCrossRefGoogle Scholar
  71. 71.
    Coffman JD, Cohen AS. Total and capillary fingertip blood flow in Raynaud’s phenomenon. N Engl J Med. 1971;285(5):259–63.PubMedCrossRefGoogle Scholar
  72. 72.
    McFadyen IJ, Housley E, MacPherson AI. Intraarterial reserpine administration in Raynaud syndrome. Arch Intern Med. 1973;132(4):526–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Varadi DP, Lawrence AM. Suppression of Raynaud’s phenomenon by methyldopa. Arch Intern Med. 1969;124(1):13–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Waldo R. Prazosin relieves Raynaud’s vasospasm. JAMA. 1979;241(10):1037.PubMedCrossRefGoogle Scholar
  75. 75.
    Clement DL, Duprez D, De Pue N. Effect of indoramin on finger circulation in patients with Raynaud disease. J Cardiovasc Pharmacol. 1986;8 Suppl 2:S84–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Brouwer RM, Wenting GJ, Man in’t Veld AJ, Schalekamp MA. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud’s phenomenon. J Cardiovasc Pharmacol. 1987;10 Suppl 3:S26–31.PubMedCrossRefGoogle Scholar
  77. 77.
    Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, et al. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud’s phenomenon. Arthritis Care Res (Hoboken). 2012;64(6):925–9.CrossRefGoogle Scholar
  78. 78.
    Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60(3):870–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Lund F. Percutaneous nitroglycerin treatment in cases of peripheral circulatory disorders, especially Raynaud’s disease. Acta Med Scand. 1948;131 Suppl 206:196–206.PubMedGoogle Scholar
  80. 80.
    Fox MJ, Leslie CL. Treatment of Raynaud’s diseases with nitroglycerine. Wis Med J. 1948;47(9):855–8.PubMedGoogle Scholar
  81. 81.
    Miller D, Waters DD, Warnica W, Szlachcic J, Kreeft J, Theroux P. Is variant angina the coronary manifestation of a generalized vasospastic disorder? N Engl J Med. 1981;304(13):763–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Clifford PC, Martin MF, Sheddon EJ, Kirby JD, Baird RN, Dieppe PA. Treatment of vasospastic disease with prostaglandin E1. Br Med J. 1980;281(6247):1031–4.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Carlson LA, Eriksson I. Femoral-artery infusion of prostaglandin E 1 in severe peripheral vascular disease. Lancet. 1973;1(7795):155–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338(20):1397–404.PubMedCrossRefGoogle Scholar
  85. 85.
    Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72(10):1696–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud’s condition score in patients with Raynaud’s phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis. 2010;69(3):588–91.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112(19):2980–5.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Medicine, Division of RheumatologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations